Sara Tolaney

Sara Tolaney is a leading breast oncologist at Dana-Farber who has contributed to numerous practice-changing clinical trials in breast cancer. Her research spans HR+ and HER2-positive breast cancers, including pivotal contributions to the development of T-DM1 adjuvant therapy and oral SERD development. She leads clinical trials investigating next-generation endocrine agents including oral SERDs for ESR1-mutated breast cancer. Her work on biomarker-driven patient selection and treatment sequences for advanced HR+ breast cancer is shaping modern clinical practice.